InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (6 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
6
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by BERNS PAUL L, Director. Director active across 6 companies, notably Jazz Pharmaceuticals plc. Cumulatively, 16 disclosures have been published. Breakdown: 1 buy · 6 sells. Total volume traded: €400k. History available since 5 August 2021. The latest transaction was filed on 18 February 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations16 total
1,250,000 sharesCommon StockSEC:0001012975-26-000565:0
Ideal exit: 19 Mar 2027 (T+270)
13,792,035 sharesCommon StockSEC:0001193125-26-277936:0
20,706 sharesCommon StockSEC:0001193125-26-277936:1
13,871 shares@ US$1.6919100.0% of flowCommon StockSEC:0001610717-25-000031:0
7,523,682 sharesCommon StockSEC:0000950170-25-012583:0
133,097 shares0Common StockSEC:0001610717-24-000555:0
171,250 shares0Common StockSEC:0001610717-24-000066:0
627,000 sharesCommon StockSEC:0000899243-23-020307:0
627,000 sharesCommon StockSEC:0000899243-21-049123
627,000 sharesCommon StockSEC:0000899243-21-049123:0
1,450 shares@ US$154.0050.0% of flowOrdinary SharesSEC:0001765581-21-000096
1,450 shares@ US$154.000.0013% mcap50.0% of flowOrdinary SharesSEC:0001765581-21-000096:0
14,584 sharesCommon StockSEC:0001209191-16-096104:0
80 sharesCommon StockSEC:0001209191-16-089483:0
233 sharesCommon StockSEC:0001209191-16-089483:2
2,220 sharesCommon StockSEC:0001209191-16-089483:1
16 of 16 declarations
About BERNS PAUL L
Paul L. Berns is a Board Member of Jazz Pharmaceuticals plc and EQRx, Inc. In this role, he participates in overseeing the activities of these companies and shaping their strategies. Berns brings significant expertise in the pharmaceutical sector, allowing him to contribute effectively to board discussions. His commitment to innovation and continuous improvement is essential for the development of these companies.
